Evolus, Inc. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Evolus, Inc. is a global performance beauty company operating in the cash-pay aesthetic market. Its primary products are Jeuveau (a botulinum toxin type A formulation) and the Evolysse collection of injectable hyaluronic acid (HA) gels. Evolysse Form and Smooth were launched in the U.S. in April 2025. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Net Revenues | $73.1 million | $68.5 million |
| Gross Profit | $48.9 million | $46.7 million |
| Gross Margin | 66.9% | 68.1% |
| Net Loss | $(10.7) million | $(18.9) million |
| Loss Per Share (Basic & Diluted) | $(0.16) | $(0.30) |
| Cash and Cash Equivalents | $49.8 million | $67.9 million (end of period) |
| Long-Term Debt | $156.4 million | $146.1 million |
| Accumulated Deficit | $(671.7) million | $(628.3) million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 6.7% year-over-year, driven by the U.S. launch of Evolysse products and international growth of Jeuveau. Jeuveau revenue was $66.0 million, while Evolysse contributed $6.7 million.
- Operating Expenses: Total operating expenses decreased 9.8% to $55.7 million, primarily due to strategic cost structure optimization reducing Selling, General, and Administrative (SG&A) expenses by $4.7 million.
- Profitability: The net loss narrowed significantly to $10.7 million from $18.9 million in the prior year. Operating loss improved to $6.8 million from $15.2 million.
- Debt Financing: On March 3, 2026, the company secured a new $30 million senior secured asset-based revolving credit facility (with a $10 million accordion feature). As of March 31, 2026, $10 million was drawn under this facility. The company also holds $150 million in New Pharmakon Term Loans.
- Contingent Royalty: The revaluation of the contingent royalty obligation payable to Evolus Founders resulted in a negligible gain of $14,000 in Q1 2026, compared to a $2.2 million loss in Q1 2025.
Guidance, Outlook, and Risks
- Product Pipeline: The company anticipates U.S. approval for Evolysse Sculpt in 2026 and Evolysse Lips in 2027. A European launch for all four Evolysse products is expected in Q2 2026.
- Liquidity: Management believes current capital resources (cash, operating cash flow, and debt facilities) are sufficient to fund operations for at least the next 12 months. The company terminated its At-the-Market (ATM) sales agreement in May 2026 without selling any shares.
- Trade and Tariff Risks: The company faces significant uncertainty regarding U.S. tariffs on imports from South Korea (Jeuveau) and France (Evolysse). New proclamations in April 2026 regarding patented pharmaceuticals may impact costs, though the scope remains uncertain.
- Regulatory Dependencies: Evolus relies on Symatese for regulatory approval of the Evolysse line in the U.S. and on Daewoong for the manufacturing of Jeuveau. Failure of these partners to maintain compliance or approvals poses a material risk.
- Market Conditions: Demand is sensitive to consumer discretionary spending, which has been impacted by inflation and geopolitical tensions. The company notes that recent tariffs have negatively affected consumer sentiment.
Investor Verification Checklist
- Verify the impact of new U.S. tariff proclamations (April 2026) on the cost of goods sold for Jeuveau and Evolysse.
- Monitor the timeline for FDA approval of Evolysse Sculpt and Lips, as delays could impact revenue projections.
- Review the terms of the new Revolving Credit Facility and the New Pharmakon Term Loans, specifically regarding covenants and interest rate exposure (SOFR-based).
- Assess the sustainability of SG&A cost reductions and whether they impact future sales growth or market share.
- Track the status of the Medytox Settlement Agreements and the associated royalty obligations through 2032.